Ratings by Goldman Sachs (Terence Flynn)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/5/2021 | Arvinas Inc. | ARVN | Maintain | Buy (N/A) |
|
Details | ||
| 8/5/2021 | United Therapeutics Corp. | UTHR | Maintain | Sell (N/A) |
|
Details | ||
| 7/19/2021 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 7/19/2021 | Bright Health Group | BHG | New Coverage | Buy (N/A) |
14.89 (16.35) |
9.81% | Details | |
| 6/14/2021 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 6/3/2021 | Merck | MRK | Maintain | Buy (N/A) |
|
Details | ||
| 6/3/2021 | Organon & Co. | OGN | New Coverage | Neutral (N/A) |
8.00 (31.66) |
295.75% | Details | |
| 5/11/2021 | Royalty Pharma | RPRX | Maintain | Neutral (N/A) |
|
Details | ||
| 4/28/2021 | Alkermes | ALKS | Maintain | Sell (N/A) |
|
Details | ||
| 4/21/2021 | Johnson & Johnson | JNJ | Maintain | Buy (N/A) |
|
Details | ||
| 3/10/2021 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 3/9/2021 | Pfizer | PFE | Maintain | Neutral (N/A) |
|
Details | ||
| 3/2/2021 | Arvinas Inc. | ARVN | Maintain | Buy (Buy) |
|
Details | ||
| 3/1/2021 | Translate Bio | TBIO | Maintain | Buy (N/A) |
|
Details | ||
| 2/24/2021 | Revance Therapeutic | RVNC | Maintain | Neutral (N/A) |
|
Details | ||
| 2/1/2021 | Eli Lilly | LLY | Maintain | Conviction Buy (N/A) |
|
Details | ||
| 12/16/2020 | Eli Lilly | LLY | Maintain | Conviction Buy (N/A) |
|
Details | ||
| 12/15/2020 | Bristol-Myers Squibb Co. | BMY | Upgrade | Conviction Buy (Buy) |
82.00 (67.17) |
-18.09% | Details | |
| 12/14/2020 | Arvinas Inc. | ARVN | Maintain | Buy (N/A) |
|
Details | ||
| 11/23/2020 | Translate Bio | TBIO | Maintain | Buy (N/A) |
|
Details | ||
| 11/19/2020 | Pfizer | PFE | New Coverage | Neutral (N/A) |
36.04 (28.15) |
-21.89% | Details | |
| 11/18/2020 | Merck | MRK | Upgrade | Conviction Buy (Buy) |
81.50 (150.76) |
84.98% | Details | |
| 11/6/2020 | Translate Bio | TBIO | Maintain | Buy (N/A) |
|
Details | ||
| 10/28/2020 | United Therapeutics Corp. | UTHR | Maintain | Sell (N/A) |
|
Details | ||
| 8/10/2020 | CytomX Therapeutics | CTMX | Maintain | Neutral (N/A) |
|
Details | ||
| 8/3/2020 | Merck | MRK | Upgrade | Buy (Neutral) |
80.24 (150.76) |
87.89% | Details | |
| 7/30/2020 | Alkermes | ALKS | Downgrade | Sell (Neutral) |
20.18 (28.48) |
41.13% | Details | |
| 7/13/2020 | Royalty Pharma | RPRX | New Coverage | Neutral (N/A) |
48.36 (41.83) |
-13.5% | Details | |
| 5/15/2020 | Kaleido Biosciences Inc. | KLDO | Maintain | Buy (N/A) |
|
Details | ||
| 5/15/2020 | Arvinas Inc. | ARVN | Maintain | Buy (N/A) |
|
Details | ||
| 4/22/2020 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 3/23/2020 | Revance Therapeutic | RVNC | Downgrade | Neutral (Buy) |
12.46 (3.65) |
-70.71% | Details | |
| 3/11/2020 | Eli Lilly | LLY | Upgrade | Conviction Buy (Buy) |
135.72 (1269.31) |
835.24% | Details | |
| 2/20/2020 | Revance Therapeutic | RVNC | Maintain | Buy (N/A) |
|
Details | ||
| 2/19/2020 | Revance Therapeutic | RVNC | Maintain | Buy (N/A) |
|
Details | ||
| 2/14/2020 | Alkermes | ALKS | Maintain | Neutral (N/A) |
|
Details | ||
| 1/31/2020 | Eli Lilly | LLY | Maintain | Buy (N/A) |
|
Details | ||
| 12/16/2019 | Arvinas Inc. | ARVN | Maintain | Buy (N/A) |
|
Details | ||
| 12/16/2019 | Amgen | AMGN | Upgrade | Conviction Buy (Buy) |
236.74 (202.44) |
-14.49% | Details | |
| 12/2/2019 | Revance Therapeutic | RVNC | New Coverage | Buy (N/A) |
17.84 (3.65) |
-79.54% | Details | |
| 12/2/2019 | Bausch Health Companies | BHC | New Coverage | Neutral (N/A) |
28.17 (6.81) |
-75.83% | Details | |
| 11/4/2019 | Bristol-Myers Squibb Co. | BMY | Maintain | Buy (N/A) |
|
Details | ||
| 10/25/2019 | Arvinas Inc. | ARVN | Maintain | Buy (N/A) |
|
Details | ||
| 10/24/2019 | Arvinas Inc. | ARVN | Upgrade | Buy (Neutral) |
18.79 (9.58) |
-49.02% | Details | |
| 10/24/2019 | Alkermes | ALKS | Maintain | Neutral (N/A) |
|
Details | ||
| 10/23/2019 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 9/9/2019 | Amgen | AMGN | Maintain | Buy (N/A) |
|
Details | ||
| 8/7/2019 | Arvinas Inc. | ARVN | Maintain | Neutral (N/A) |
|
Details | ||
| 8/6/2019 | Arvinas Inc. | ARVN | Maintain | Neutral (N/A) |
|
Details | ||
| 7/15/2019 | Alkermes | ALKS | Upgrade | Neutral (Sell) |
22.94 (20.18) |
-12.03% | Details | |
| 5/28/2019 | Pfizer | PFE | New Coverage | Conviction Buy (N/A) |
41.95 (28.15) |
-32.9% | Details | |
| 5/28/2019 | Merck | MRK | New Coverage | Neutral (N/A) |
81.17 (150.76) |
85.73% | Details | |
| 5/28/2019 | Eli Lilly | LLY | New Coverage | Buy (N/A) |
116.79 (1269.31) |
986.83% | Details | |
| 5/28/2019 | Johnson & Johnson | JNJ | New Coverage | Buy (N/A) |
138.85 (272.74) |
96.43% | Details | |
| 5/28/2019 | Bristol-Myers Squibb Co. | BMY | New Coverage | Buy (N/A) |
46.81 (67.17) |
43.49% | Details | |
| 5/28/2019 | Allergen | AGN | New Coverage | Neutral (N/A) |
135.51 (193.02) |
42.44% | Details | |
| 5/28/2019 | Abbvie | ABBV | New Coverage | Neutral (N/A) |
80.06 (263.27) |
228.84% | Details | |
| 5/28/2019 | Gilead Sciences | GILD | Downgrade | Sell (Neutral) |
66.89 (147.53) |
120.56% | Details | |
| 3/25/2019 | Magenta Therapeutics | MGTA | Downgrade | Neutral (Buy) |
18.28 (0.70) |
-96.17% | Details | |
| 3/25/2019 | Kaleido Biosciences Inc. | KLDO | New Coverage | Buy (N/A) |
13.52 (0.00) |
-100% | Details | |
| 3/21/2019 | Biogen | BIIB | Downgrade | Neutral (Buy) |
320.59 (218.68) |
-31.79% | Details | |
| 1/17/2019 | Amgen | AMGN | Maintain | Buy (N/A) |
|
Details | ||
| 1/3/2019 | Celgene | CELG | Upgrade | Neutral (Sell) |
66.64 (108.24) |
62.42% | Details | |
| 12/19/2018 | Alkermes | ALKS | Downgrade | Sell (Neutral) |
32.95 (22.94) |
-30.38% | Details | |
| 12/14/2018 | CytomX Therapeutics | CTMX | Upgrade | Buy (Neutral) |
15.01 (3.56) |
-76.28% | Details | |
| 10/22/2018 | Arvinas Inc. | ARVN | New Coverage | Neutral (N/A) |
15.45 (18.79) |
21.62% | Details | |
| 10/15/2018 | CytomX Therapeutics | CTMX | New Coverage | Neutral (N/A) |
15.32 (15.01) |
-2.02% | Details |
